The expiration of the investment banking agreement might initially concern investors about funding and support for Oragenics' projects. However, the promising development of ONP-002 and the growing market for concussion treatments could offset these concerns. The decision not to extend the banking agreement is attributed to market conditions, which might be temporary. The focus on ONP-002's development, given its potential in a significant and expanding market, could maintain investor interest and potentially attract new investment opportunities.